EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF(V600E) Mutated Parent- and Vemurafenib-Resistant Melanoma

The clinical outcomes of malignant melanoma have improved with the introduction of mitogen-activated protein kinase kinase (MEK) inhibitors. However, off-target toxicities of the MEK inhibitor trametinib (TMB) often result in dose interruption and discontinuation of therapy. The purpose of this stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Yige, Rathod, Drishti, Abo-Ali, Ehab M., Dukhande, Vikas V., Patel, Ketan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836218/
https://www.ncbi.nlm.nih.gov/pubmed/31581483
http://dx.doi.org/10.3390/pharmaceutics11100504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836218/
https://www.ncbi.nlm.nih.gov/pubmed/31581483
http://dx.doi.org/10.3390/pharmaceutics11100504

Ejemplares similares